By Edward Winnick

SAN FRANCISCO (GenomeWeb News) – Caliper Life Sciences hopes to receive the CE IVD Mark this year for its new LabChip Dx instrument as it looks to potential partnerships to help build content for the new platform, President and CEO Kevin Hrusovsky told GenomeWeb Daily News.

Speaking in advance of Caliper's presentation Thursday at the JP Morgan Healthcare Conference here, he also said his firm believes it has the tools pharma firms will want in developing companion diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.